Tilray Medical Backs Successful Fibromyalgia Study on Cannabinoids for Pain and Symptom Relief

LISBON, Portugal, Sept. 09, 2024 – Tilray Medical, a division of Tilray Brands, Inc. and a global leader in medical cannabis, announced a new scientific publication titled, "Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS)." This study evaluates the real-world effects of cannabinoid treatments on fibromyalgia (FM) patients under medical supervision.

The TOMAS study, involving patients with an average age of 52, explored the impact of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The findings shed light on how cannabinoids influence health outcomes, particularly focusing on pain relief, sleep improvement, and overall quality of life.

Under the guidance and supervision of medical professionals, the study showed notable improvements in pain levels, sleep quality, and the overall quality of life for those with fibromyalgia. Additionally, there was a significant reduction in the use of other medications, suggesting that cannabinoids could be an effective and cost-efficient treatment for this condition. These findings offer valuable insights for the medical and scientific communities regarding the use of cannabinoids in managing chronic pain and enhancing the quality of life for fibromyalgia patients.

José Tempero, Tilray’s Medical Director, remarked, "The study’s outcomes are promising and provide hope for fibromyalgia patients seeking effective treatments. At Tilray, we are devoted to conducting thorough scientific research to ensure our treatments are evidence-based and can enhance patient care. We believe these results represent a significant advancement in understanding the therapeutic potential of cannabinoids and their role in managing chronic pain."

Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, stated, "Tilray’s participation in this study highlights our commitment to advancing medical research and unlocking the full therapeutic potential of medical cannabis. The positive outcomes of the TOMAS study for fibromyalgia patients underscore the potential of cannabinoids as a safe and effective treatment for chronic pain and associated symptoms. Tilray Medical remains dedicated to advancing the science of medical cannabis and empowering patients and healthcare practitioners with the knowledge needed to make informed health decisions."

Tilray Medical’s mission is to transform lives and promote dignity for patients in need through access to medical cannabis. Currently, Tilray is a leading provider of EU-GMP certified medical cannabis products in over 20 countries, offering a broad range of THC and CBD products. Tilray has supported medical trials globally, including in Europe, Canada, the United States, Australia, and Latin America, to study the efficacy of medical cannabis for various conditions such as pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol use disorders.

About Tilray Medical:
Tilray Medical is committed to transforming lives and promoting dignity for patients through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and Navcora. Tilray has grown from being one of the first approved licensed producers of medical cannabis in Canada to establishing the first GMP-certified cannabis production facilities in Europe, initially in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, spanning 20 countries and five continents.

About Tilray Brands:
Tilray Brands, Inc. is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. Tilray aims to be a premium lifestyle company with a diverse portfolio of brands and innovative products that inspire joy and create memorable experiences. The company supports over 40 brands in more than 20 countries, offering cannabis products, hemp-based foods, and craft beverages.